Repligen (RGEN) ROE: History & Chart

Repligen Corporation(RGEN)

Medical - Instruments & Supplies · Waltham, MA

$178.18-11.32 (-5.97%)

Delayed quote: Oct 6, 2026, 1:00 PM EDT

About Repligen Corporation

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

Waltham, MA

2,000 employees

www.repligen.com

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Olivier Loeillot

View full financials

RGEN Return on Equity (ROE) Metrics

RETURN ON EQUITY (ROE)

1.97%

RETURN ON EQUITY (ROE) AVG TTM

1.23%

RETURN ON EQUITY (ROE) AVG 3Y

1.26%

RETURN ON EQUITY (ROE) AVG 5Y

3.84%

RETURN ON EQUITY (ROE) AVG 10Y

4.04%

RETURN ON EQUITY (ROE) AVG 15Y

4.47%

RETURN ON EQUITY (ROE) AVG 20Y

3.73%

CURRENT VS TTM AVG

+60.10%

CURRENT VS 3Y AVG

+56.62%

CURRENT VS 5Y AVG

-48.79%

CURRENT VS 10Y AVG

-51.34%

CURRENT VS 15Y AVG

-56.04%

CURRENT VS 20Y AVG

-47.31%

SECTOR MEDIAN · HEALTHCARE

-40.89%

median of 684 covered companies

CURRENT VS SECTOR MEDIAN

+104.81%

vs the sector median at left

NAME	MARKET CAP	RETURN ON EQUITY (ROE)	TTM	3Y	5Y
Repligen Corporation (RGEN)	$10.06B	1.97%	1.23%	1.26%	3.84%
Molina Healthcare, Inc. (MOH)vs ›	$10.01B	-0.17%	18.91%	22.60%	24.60%
Bio-Rad Laboratories, Inc. (BIO)vs ›	$9.99B	3.10%	-8.94%	-15.72%	1.14%
The Ensign Group, Inc. (ENSG)vs ›	$10.14B	15.51%	15.81%	15.92%	17.27%
Align Technology, Inc. (ALGN)vs ›	$10.20B	9.77%	10.54%	10.84%	19.93%
ImmunityBio, Inc. (IBRX)vs ›	$10.37B	N/A	77.45%	86.84%	112.62%
Globus Medical, Inc. (GMED)vs ›	$10.41B	11.23%	7.12%	6.90%	7.16%
Henry Schein, Inc. (HSIC)vs ›	$9.66B	12.77%	11.88%	12.69%	13.50%
Krystal Biotech, Inc. (KRYS)vs ›	$9.62B	17.77%	13.11%	0.20%	-3.65%
Vaxcyte, Inc. (PCVX)vs ›	$9.49B	-38.59%	-21.29%	-24.61%	-26.58%

NAME

MARKET CAP

RETURN ON EQUITY (ROE)

TTM

Repligen Corporation (RGEN)

$10.06B

1.97%

1.23%

1.26%

3.84%

Molina Healthcare, Inc. (MOH)vs ›

$10.01B

-0.17%

18.91%

22.60%

24.60%

Bio-Rad Laboratories, Inc. (BIO)vs ›

$9.99B

3.10%

-8.94%

-15.72%

1.14%

The Ensign Group, Inc. (ENSG)vs ›

$10.14B

15.51%

15.81%

15.92%

17.27%

Align Technology, Inc. (ALGN)vs ›

$10.20B

9.77%

10.54%

10.84%

19.93%

ImmunityBio, Inc. (IBRX)vs ›

$10.37B

N/A

77.45%

86.84%

112.62%

Globus Medical, Inc. (GMED)vs ›

$10.41B

11.23%

7.12%

6.90%

7.16%

Henry Schein, Inc. (HSIC)vs ›

$9.66B

12.77%

11.88%

12.69%

13.50%

Krystal Biotech, Inc. (KRYS)vs ›

$9.62B

17.77%

13.11%

0.20%

-3.65%

Vaxcyte, Inc. (PCVX)vs ›

$9.49B

-38.59%

-21.29%

-24.61%

-26.58%

Return on Equity (ROE) FAQ

What is the return on equity (ROE) for Repligen Corporation (RGEN)?

The return on equity (ROE) for RGEN stock is 1.97%.

Is Repligen Corporation's return on equity (ROE) high or low?

The return on equity (ROE) of 1.97% is 49% below its 5-year average of 3.84%, near the low end of its 5-year range (-1.29%–9.73%).

What is the TTM average return on equity (ROE) for Repligen Corporation (RGEN)?

The TTM average return on equity (ROE) for RGEN stock is 1.23%.

What is the 3Y average return on equity (ROE) for Repligen Corporation (RGEN)?

The 3Y average return on equity (ROE) for RGEN stock is 1.26%.

What is the 5Y average return on equity (ROE) for Repligen Corporation (RGEN)?

The 5Y average return on equity (ROE) for RGEN stock is 3.84%.

What is the 10Y average return on equity (ROE) for Repligen Corporation (RGEN)?

The 10Y average return on equity (ROE) for RGEN stock is 4.04%.

What is the 15Y average return on equity (ROE) for Repligen Corporation (RGEN)?

The 15Y average return on equity (ROE) for RGEN stock is 4.47%.

What is the 20Y average return on equity (ROE) for Repligen Corporation (RGEN)?

The 20Y average return on equity (ROE) for RGEN stock is 3.73%.

DATE	RETURN ON EQUITY (ROE)
2026-06-30	1.97%
2026-03-31	2.44%
2025-12-31	2.32%
2025-09-30	0.08%
2025-06-30	-0.67%
2025-03-31	-1.16%
2024-12-31	-1.29%
2024-09-30	-0.85%
2024-06-30	0.02%
2024-03-31	0.74%
2023-12-31	1.35%
2023-09-30	5.07%
2023-06-30	6.30%
2023-03-31	7.95%
2022-12-31	9.73%
2022-09-30	9.06%
2022-06-30	8.83%
2022-03-31	8.25%
2021-12-31	7.33%
2021-09-30	6.93%
2021-06-30	6.23%
2021-03-31	5.11%
2020-12-31	3.92%
2020-09-30	3.90%
2020-06-30	2.81%
2020-03-31	2.17%
2019-12-31	2.02%
2019-09-30	2.24%
2019-06-30	3.02%
2019-03-31	3.40%
2018-12-31	2.70%
2018-09-30	3.82%
2018-06-30	3.85%
2018-03-31	4.81%
2017-12-31	4.79%
2017-09-30	3.68%
2017-06-30	9.26%
2017-03-31	7.42%
2016-12-31	6.92%
2016-09-30	4.15%
2016-06-30	5.07%
2016-03-31	6.24%
2015-12-31	7.61%
2015-09-30	7.15%
2015-06-30	6.44%
2015-03-31	6.10%
2014-12-31	7.31%
2014-09-30	10.38%
2014-06-30	14.12%
2014-03-31	16.57%
2013-12-31	15.49%
2013-09-30	22.28%
2013-06-30	19.73%
2013-03-31	17.47%
2012-12-31	16.83%
2012-09-30	6.25%
2012-06-30	4.95%
2012-03-31	2.59%
2011-09-30	-1.63%
2011-06-30	-1.62%
2011-03-31	-0.06%
2010-12-31	0.52%
2010-09-30	-0.54%
2010-06-30	-2.92%
2010-03-31	-6.15%
2009-12-31	-7.60%
2009-09-30	-7.05%
2009-06-30	-5.33%
2009-03-31	8.31%
2008-12-31	7.34%
2008-09-30	6.84%
2008-06-30	62.03%
2008-03-31	57.88%
2007-12-31	59.89%
2007-09-30	60.49%
2007-06-30	-2.84%
2007-03-31	-3.48%
2006-12-31	-6.33%
2006-09-30	-7.08%
2006-06-30	-5.39%
2006-03-31	2.74%
2005-12-31	4.21%
2005-09-30	4.22%
2005-06-30	-0.57%
2005-03-31	-12.28%
2004-12-31	-23.54%
2004-09-30	-31.14%
2004-06-30	-30.72%
2004-03-31	-35.16%
2003-12-31	-26.34%
2003-09-30	-20.51%
2003-06-30	-16.19%
2003-03-31	-18.48%

DATE

RETURN ON EQUITY (ROE)

2026-06-30

1.97%

2026-03-31

2.44%

2025-12-31

2.32%

2025-09-30

0.08%

2025-06-30

-0.67%

2025-03-31

-1.16%

2024-12-31

-1.29%

2024-09-30

-0.85%

2024-06-30

0.02%

2024-03-31

0.74%

2023-12-31

1.35%

2023-09-30

5.07%

2023-06-30

6.30%

2023-03-31

7.95%

2022-12-31

9.73%

2022-09-30

9.06%

2022-06-30

8.83%

2022-03-31

8.25%

2021-12-31

7.33%

2021-09-30

6.93%

2021-06-30

6.23%

2021-03-31

5.11%

2020-12-31

3.92%

2020-09-30

3.90%

2020-06-30

2.81%

2020-03-31

2.17%

2019-12-31

2.02%

2019-09-30

2.24%

2019-06-30

3.02%

2019-03-31

3.40%

2018-12-31

2.70%

2018-09-30

3.82%

2018-06-30

3.85%

2018-03-31

4.81%

2017-12-31

4.79%

2017-09-30

3.68%

2017-06-30

9.26%

2017-03-31

7.42%

2016-12-31

6.92%

2016-09-30

4.15%

2016-06-30

5.07%

2016-03-31

6.24%

2015-12-31

7.61%

2015-09-30

7.15%

2015-06-30

6.44%

2015-03-31

6.10%

2014-12-31

7.31%

2014-09-30

10.38%

2014-06-30

14.12%

2014-03-31

16.57%

2013-12-31

15.49%

2013-09-30

22.28%

2013-06-30

19.73%

2013-03-31

17.47%

2012-12-31

16.83%

2012-09-30

6.25%

2012-06-30

4.95%

2012-03-31

2.59%

2011-09-30

-1.63%

2011-06-30

-1.62%

2011-03-31

-0.06%

2010-12-31

0.52%

2010-09-30

-0.54%

2010-06-30

-2.92%

2010-03-31

-6.15%

2009-12-31

-7.60%

2009-09-30

-7.05%

2009-06-30

-5.33%

2009-03-31

8.31%

2008-12-31

7.34%

2008-09-30

6.84%

2008-06-30

62.03%

2008-03-31

57.88%

2007-12-31

59.89%

2007-09-30

60.49%

2007-06-30

-2.84%

2007-03-31

-3.48%

2006-12-31

-6.33%

2006-09-30

-7.08%

2006-06-30

-5.39%

2006-03-31

2.74%

2005-12-31

4.21%

2005-09-30

4.22%

2005-06-30

-0.57%

2005-03-31

-12.28%

2004-12-31

-23.54%

2004-09-30

-31.14%

2004-06-30

-30.72%

2004-03-31

-35.16%

2003-12-31

-26.34%

2003-09-30

-20.51%

2003-06-30

-16.19%

2003-03-31

-18.48%

Return on Equity (ROE): 1.97%

RGEN Return on Equity (ROE)

RGEN Average Return on Equity (ROE) Chart

RGEN Current vs Average Return on Equity (ROE) Chart

RGEN Return on Equity (ROE) Metrics

RGEN Competitors' Return on Equity (ROE)

Return Analysis

Return on Equity (ROE) Formula & Definition

Return on Equity (ROE) FAQ

RGEN Return on Equity (ROE) History

Related Metrics